Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015743 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL1775528 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL14064188 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22983972 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL2460807 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22984023 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22983968 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL23517951 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL7535874 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL6250998 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100015052-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE AS (GB) | 2010-01-21 | — | — | US | claimed |
| EP-2029182-A2 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE Healthcare AS (NO) | 2009-03-04 | — | — | EP | claimed |
| WO-2007148083-A2 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE AS (NO) | 2007-12-27 | — | — | WO | claimed |
| US-8496910-B2 | Stabilisation of radiopharmaceutical precursors | GE HEALTHCARE AS (NO) | 2013-07-30 | — | — | US | disclosed |
| EP-2368580-A1 | Stabilisation of fluorothymidine precursors | GE HEALTHCARE AS (NO) | 2011-09-28 | — | — | EP | disclosed |
| US-20100015052-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE AS (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2029182-A2 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE Healthcare AS (NO) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007148083-A2 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE AS (NO) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015052-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | TYMP, SLC29A1, SAMHD1 | TYMS 4/4885POLB 233/4885TYMP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.